Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | SDCBP | O00560 | 1/20 | 0.41 |
| ▸ | SDC2 | P34741 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23629905 | 1.00 | CTSS (0.51) | CTSSCTSKSDCBPSDC2PSENEN | |
| SCHEMBL8903579 | 0.97 | CTSS (0.53) | CTSSCTSKSDCBPSDC2PSENEN | |
| SCHEMBL31069956 | 0.89 | KMT2A (0.46) | CTSSCTSKSDCBPSDC2KMT2A | |
| SCHEMBL4754096 | 0.86 | CTSK (0.51) | CTSSCTSKSDCBPSDC2KMT2A | |
| SCHEMBL4754099 | 0.86 | CTSK (0.51) | CTSSCTSKSDCBPSDC2KMT2A | |
| SCHEMBL8140353 | 0.86 | KMT2A (0.49) | CTSSCTSKSDCBPSDC2KMT2A | |
| SCHEMBL31314679 | 0.86 | KMT2A (0.49) | CTSSCTSKSDCBPSDC2KMT2A | |
| SCHEMBL27383483 | 0.84 | CTSS (0.57) | CTSSCTSKSDCBPSDC2PSENEN | |
| SCHEMBL18562066 | 0.83 | CTSK (0.61) | CTSSCTSKPSENENCA2CA1 | |
| SCHEMBL7285160 | 0.83 | CTSK (0.61) | CTSSCTSKPSENENCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-112714649-B | Cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-3848054-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-112714649-A | Novel cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2021-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | CTSS 3687/4885CTSK 2945/4885SDCBP 1170/4885 |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | CTSS 3192/4885CTSK 2449/4885SDCBP 1076/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | CTSS 3192/4885CTSK 2449/4885SDCBP 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.